Cargando…

Drug-drug interaction with oral antivirals for the early treatment of COVID-19

Detalles Bibliográficos
Autores principales:	Vuorio, Alpo, Raal, Frederick, Kovanen, Petri T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715460/ https://www.ncbi.nlm.nih.gov/pubmed/36470504 http://dx.doi.org/10.1016/j.ijid.2022.11.039

Ejemplares similares

Monkeypox is a global public health emergency: The role of repurposing cholesterol lowering drugs not to be forgotten
por: Vuorio, Alpo, et al.
Publicado: (2022)

Opportunities for preventing further endothelial dysfunction in pregnant COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022)

Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction
por: Kovanen, Petri T., et al.
Publicado: (2021)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy
por: Vuorio, Alpo, et al.
Publicado: (2022)

Comment on: “Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry”
por: Vuorio, Alpo, et al.
Publicado: (2021)

Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation
por: Vuorio, Alpo, et al.
Publicado: (2021)

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
por: Vuorio, Alpo, et al.
Publicado: (2023)

Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2020)

Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment
por: Vuorio, Alpo, et al.
Publicado: (2021)

Elevated Lipoprotein(a) and Cerebral Venous Sinus Thrombosis in COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke
por: Vuorio, Alpo, et al.
Publicado: (2021)

Mucormycosis and glucose‐regulated protein 78 in COVID‐19: Amenable to statin treatment?
por: Vuorio, Alpo, et al.
Publicado: (2021)

Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge
por: Vuorio, Alpo, et al.
Publicado: (2021)

Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022)

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
por: Vuorio, Alpo, et al.
Publicado: (2023)

Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond
por: Vuorio, Alpo, et al.
Publicado: (2021)

Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition
por: Vuorio, Alpo, et al.
Publicado: (2021)

Drug-drug interaction with oral antivirals for early treatment of COVID-19 – Authors’ reply
por: Larsen, Carsten Schade
Publicado: (2023)

Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism
por: Vuorio, Alpo, et al.
Publicado: (2021)

Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing
por: Vuorio, Alpo, et al.
Publicado: (2022)

SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease
por: Kovanen, Petri T., et al.
Publicado: (2023)

Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
por: Vuorio, Alpo, et al.
Publicado: (2018)

Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2014)

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions
por: Back, David, et al.
Publicado: (2020)

Antiviral Drugs for Viral Pneumonia
por: Bansal, Tapesh
Publicado: (2023)

Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
por: Larsen, Carsten Schade
Publicado: (2022)

Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series
por: Vazquez, Sara R., et al.
Publicado: (2022)

Interactions of recommended COVID-19 drugs with commonly used psychotropics
por: Chatterjee, Seshadri Sekhar, et al.
Publicado: (2020)

Potential interactions between COVID-19 vaccines and antiepileptic drugs
por: Kow, Chia Siang, et al.
Publicado: (2021)

Sars-Cov-2 and risk of antiviral drug resistance
por: Vitiello, Antonio
Publicado: (2021)

Antiviral Drugs for Treatment of Patients Infected with Pandemic (H1N1) 2009 Virus
por: Hartley, David M., et al.
Publicado: (2009)

Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19
por: Sato, Ken, et al.
Publicado: (2021)

Nanoformulation-Based Antiviral Combination Therapy for Treatment of COVID-19
por: Keshmiri Neghab, Hoda, et al.
Publicado: (2020)

Drug-drug Interactions: The Importance of Medication Reconciliation
por: Makiani, Mahin Jamshidi, et al.
Publicado: (2017)

Cationic drugs and COVID-19
por: Brenna, Oreste Vittore, et al.
Publicado: (2020)

ACE2, a drug target for COVID-19 treatment?
por: Liu, Yang, et al.
Publicado: (2022)

Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment
por: Sahin, Gokben, et al.
Publicado: (2022)

Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants
por: Bojkova, Denisa, et al.
Publicado: (2022)

Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment
por: Jin, Tianru, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nipc1u1tinjrd2098d8fgcdmd3